Cyclosporine
- Generic Name
- Cyclosporine
- Brand Names
- Cequa, Gengraf, Neoral, Restasis, Sandimmune, Verkazia, Vevye, Ikervis
- Drug Type
- Small Molecule
- Chemical Formula
- C62H111N11O12
- CAS Number
- 59865-13-3
- Unique Ingredient Identifier
- 83HN0GTJ6D
- Background
Cyclosporine is a calcineurin inhibitor known for its immunomodulatory properties that prevent organ transplant rejection and treat various inflammatory and autoimmune conditions. It is isolated from the fungus Beauveria nivea. Initially manufactured by Sandoz and approved for use by the FDA in 1983, cyclosporine is now available in various products by Novar...
- Indication
Cyclosporine is approved for a variety of conditions. Firstly, it is approved for the prophylaxis of organ rejection in allogeneic kidney, liver, and heart transplants. It is also used to prevent bone marrow transplant rejection. For the above indications, cyclosporine can be used in conjunction with azathioprine and corticosteroids. Finally, cyclosporine ca...
- Associated Conditions
- Atopic Dermatitis, Bone Marrow Transplant Rejection, Chronic transplant rejection, Connective Tissue Disorders, Dry Eyes, Graft-versus-host Disease (GVHD), Heart Transplant Rejection, Immune Thrombocytopenia (ITP), Interstitial Cystitis, Juvenile Idiopathic Arthritis (JIA), Kidney Transplant Rejection, Liver Transplant Rejection, Lupus Nephritis, Nephrotic Syndrome, Ocular Rosacea, Rheumatoid Arthritis, Severe Ulcerative Colitis, Steroid Dependent Nephrotic Syndrome, Steroid Resistant Nephrotic Syndrome, Uveitis, Vernal Keratoconjunctivitis, Blistering disorder, Refractory Ulcerative colitis, Severe Psoriasis, Severe, active Rheumatoid arthritis, Severe, recalcitrant Plaque psoriasis, Suppressed tear production
- Associated Therapies
- -
Stem Cell Transplantation for Metastatic Solid Tumors
- First Posted Date
- 1999-11-04
- Last Posted Date
- 2021-11-10
- Target Recruit Count
- 42
- Registration Number
- NCT00001880
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States
Drug Therapy in Lupus Nephropathy
- Conditions
- First Posted Date
- 1999-11-04
- Last Posted Date
- 2008-04-09
- Target Recruit Count
- 45
- Registration Number
- NCT00001212
- Locations
- 🇺🇸
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), Bethesda, Maryland, United States
Medical Treatment for Diamond Blackfan Anemia
- Conditions
- First Posted Date
- 1999-11-04
- Last Posted Date
- 2008-03-04
- Target Recruit Count
- 25
- Registration Number
- NCT00001749
- Locations
- 🇺🇸
National Heart, Lung and Blood Institute (NHLBI), Bethesda, Maryland, United States
Myocarditis Treatment Trial
- Conditions
- First Posted Date
- 1999-10-28
- Last Posted Date
- 2023-04-18
- Lead Sponsor
- University of Utah
- Registration Number
- NCT00000524
Phase II Study of Bone Marrow Transplantation Using Related Donors in Patients With Aplastic Anemia
- Conditions
- First Posted Date
- 1999-10-19
- Last Posted Date
- 2005-06-24
- Lead Sponsor
- National Center for Research Resources (NCRR)
- Target Recruit Count
- 10
- Registration Number
- NCT00004323
- Locations
- 🇺🇸
Center for Health Sciences, Los Angeles, California, United States
Phase II Randomized Study of Muromonab-CD3, Cyclosporine, Methylprednisolone, and Prednisone in Patients With Giant Cell Myocarditis
- Conditions
- First Posted Date
- 1999-10-19
- Last Posted Date
- 2010-09-09
- Lead Sponsor
- Mayo Clinic
- Target Recruit Count
- 40
- Registration Number
- NCT00004482
- Locations
- 🇺🇸
Mayo Clinic, Rochester, Minnesota, United States
Bone Marrow Transplantation in Treating Children With Sickle Cell Disease
- Conditions
- First Posted Date
- 1999-10-19
- Last Posted Date
- 2008-09-10
- Lead Sponsor
- Fred Hutchinson Cancer Center
- Target Recruit Count
- 50
- Registration Number
- NCT00004485
- Locations
- 🇺🇸
Children's Hospital of Oakland, Oakland, California, United States
🇺🇸Fred Hutchinson Cancer Research Center, Seattle, Washington, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.